SCHEMBL22979629

SCHEMBL22979629

N#Cc1cccc2c1nc(Cl)n1nc(-c3cn[nH]c3)nc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CD O00329 1/20 0.37
XDH P47989 3/20 0.34
KDM5A P29375 1/20 0.33
PIK3CA P42336 2/20 0.33
PDE10A Q9Y233 1/20 0.32
IRAK4 Q9NWZ3 1/20 0.32
ADORA2A P29274 1/20 0.32
PIM1 P11309 1/20 0.31
GABRP O00591 1/20 0.31
GABRD O14764 1/20 0.31
GABRA1 P14867 1/20 0.31
GABRB1 P18505 1/20 0.31
GABRG2 P18507 1/20 0.31
GABRB3 P28472 1/20 0.31
GABRA5 P31644 1/20 0.31
GABRA3 P34903 1/20 0.31
GABRA2 P47869 1/20 0.31
GABRB2 P47870 1/20 0.31
GABRA4 P48169 1/20 0.31
GABRE P78334 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22988089 0.81 HSP90AB1 (0.41) ADORA2A
SCHEMBL22987675 0.80 EGFR (0.38) XDHADORA2AADORA3
SCHEMBL22987741 0.80 PIK3CD (0.41) PIK3CDADORA2AADORA3ADORA1
SCHEMBL22987742 0.79 JAK2 (0.37) KDM5APDE10AADORA2AADORA3ADORA1
SCHEMBL29646457 0.79 PIK3CD (0.33) PIK3CDPDE10AIRAK4ADORA2AADORA3
SCHEMBL22979970 0.79 PIK3CD (0.33) PIK3CDPDE10AIRAK4ADORA2AADORA3
SCHEMBL22979908 0.78 ADORA3 (0.50) XDHGABRPGABRDGABRA1GABRB1
SCHEMBL22979323 0.77 GABRP (0.45) XDHKDM5AGABRPGABRDGABRA1
SCHEMBL22988110 0.76 KDM5A (0.36) PIK3CDKDM5APIK3CAIRAK4PIM1
SCHEMBL31150086 0.76 PDE10A (0.33) PIK3CDKDM5APDE10APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2023-04-13 US disclosed
EP-4013508-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES Bayer Aktiengesellschaft (DE) 2022-06-22 EP disclosed
CN-114466850-A [1,2,4] triazolo [1,5-C ] quinazolin-5-amines 拜耳股份有限公司 2022-05-10 CN disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed
WO-2021028382-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES BAYER AKTIENGESELLSCHAFT (DE) 2021-02-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230113037-A1 [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINES AHR, HRH4, HRH1 PIK3CD 2082/4885XDH 1545/4885KDM5A 378/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.